Test Price
2,800 AED✅ Home Collection Available
MAT2A Gene Familial Thoracic Aortic Aneurysm DNA Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by Consultant Medical Genetics.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
MAT2A gene analysis using Next-Generation Sequencing (NGS) identifies pathogenic variants associated with familial thoracic aortic aneurysm, a condition that can lead to sudden aortic dissection if undetected. This genetic test offers 99.9% diagnostic sensitivity to guide cardiologists, clinical geneticists, and primary care physicians in personalized surveillance and prophylactic interventions. Conducted at DNA Labs UAE under Dubai Healthcare City regulation, the analysis covers full exon and intron boundary regions to capture single nucleotide variants and small insertions or deletions.
| Feature | Our MAT2A NGS Test | Closest Alternative |
|---|---|---|
| Precision | >99.9% diagnostic sensitivity for SNVs/indels across the entire MAT2A gene | ~95% with targeted Sanger sequencing; limited to known hotspots |
| Method | Next-Generation Sequencing (NGS) with deep coverage and full exon/intron boundaries | Single-gene Sanger or panel-based testing; may miss deep intronic variants |
| Turnaround Time | 3–4 weeks | 6–8 weeks (often requiring international send-out) |
Physician Insight & Safety Protocols
“Genetic testing for MAT2A provides critical information about hereditary aortic aneurysm risk, yet results must always be interpreted alongside comprehensive family history and clinical examination. A negative result does not eliminate risk, whereas a positive result requires compassionate multidisciplinary counselling involving cardiology and clinical genetics. Our priority is to support long-term vascular health through precise molecular diagnosis and informed surveillance planning.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics
DHA Registration ID: 9294403
Medication Advisory
Do not discontinue, alter, or adjust any prescribed medication—including beta-blockers, angiotensin receptor blockers, or antihypertensive therapy—without direct consultation with your treating physician. Abrupt discontinuation may increase risk of aortic complications.
Exclusion Criteria & Preparation
Individuals with active febrile illness, recent blood transfusion (<48 hours), or on high-dose anticoagulants preventing safe phlebotomy require physician clearance prior to sample collection. Discontinue high-dose biotin (vitamin B7) supplements at least 72 hours before blood draw if advised by your clinician.
Emergency Red Flags
Sudden, severe chest or back pain, shortness of breath, syncope, or signs suggestive of aortic dissection constitute a medical emergency. This genetic screening does not replace immediate clinical evaluation; seek emergency medical attention without delay if symptoms arise.
Patient FAQ & Clinical Guidance
1. Who should consider the MAT2A genetic test for familial thoracic aortic aneurysm?
First-degree relatives of individuals with confirmed thoracic aortic aneurysm or dissection, patients with syndromic features suggestive of hereditary aortopathy (e.g., Marfan-like phenotype), and any adult seeking proactive cardiovascular risk assessment with a documented family history of aortic disease should consider MAT2A genetic testing. Early molecular diagnosis enables personalized surveillance intervals and timely prophylactic interventions.
2. How accurate is the MAT2A NGS test and what does a positive result mean?
The MAT2A NGS assay delivers >99.9% analytical sensitivity for detecting pathogenic single-nucleotide variants and small indels across all coding exons and flanking intronic regions. A positive result confirms a germline genetic predisposition to thoracic aortic aneurysm, enabling strict blood pressure management, regular aortic imaging surveillance (echocardiography, CT, or MRI), and informed discussion of prophylactic aortic root or ascending aorta repair when diameter thresholds are met.
3. What is the sample collection process and turnaround time in the UAE?
A standard peripheral venous blood sample (4–6 mL in EDTA tube) is collected by a DHA-licensed VIP mobile phlebotomist at your home or preferred location within Dubai and the Northern Emirates. Temperature-controlled cold-chain transport preserves specimen integrity. Results are reported within 3 to 4 weeks, followed by a telephonic consultation with the Consultant Medical Genetics to explain clinical implications and recommended next steps.
4. How are my genetic data and health information protected under UAE law?
All genetic data, clinical records, and personal health information are processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Results are shared only with the ordering physician and the patient through secure, encrypted channels. DNA Labs UAE maintains ISO 9001:2015 certification for quality management and adheres to DHA standards for genetic data confidentiality.
UAE Regulatory & Data Privacy Adherence
Regulatory Framework: This diagnostic service operates under DHA Facility License No. 1143 and complies with all applicable UAE federal health regulations. Clinical testing and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent and patient safety.
Data Protection: Patient genetic information and personal data are safeguarded under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). All electronic health records are managed in accordance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, guaranteeing end-to-end encryption and access control.
Quality Certification: ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139) ensures consistent quality, traceability, and continuous improvement across all laboratory operations at DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | MAT2A Gene Sequencing for Familial Thoracic Aortic Aneurysm |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Extracted DNA, or FTA Card Dried Blood Spot |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coding Regions & Flanking Intronic Boundaries |
| ICD-10-CM Code | I71.2, Z15.8 |
| LOINC Code | 96458-9 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians